聚焦ASCO 2026:关键数据背后的创新趋势与价值判断。Improved outcomes with checkpoint inhibitors (Abs:11000): A TriNetX cohort of 3,429 matched IO patients showed that concurrent GLP-1 use led to improvements in survival (5-year mortality of 32% vs 45%), and fewer adverse events, with a pyrexia OR of 0.73.
聚焦ASCO 2026:关键数据背后的创新趋势与价值判断。Improved outcomes with checkpoint inhibitors (Abs:11000): A TriNetX cohort of 3,429 matched IO patients showed that concurrent GLP-1 use led to improvements in survival (5-year mortality of 32% vs 45%), and fewer adverse events, with a pyrexia OR of 0.73.
聚焦ASCO 2026:关键数据背后的创新趋势与价值判断。Improved outcomes with checkpoint inhibitors (Abs:11000): A TriNetX cohort of 3,429 matched IO patients showed that concurrent GLP-1 use led to improvements in survival (5-year mortality of 32% vs 45%), and fewer adverse events, with a pyrexia OR of 0.73.
覆盖 2026 年,全文共 19 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
重点分析了ASCO等议题。